Bisphosphonate conjugation to proteins as a means to impart bone affinity

Biotechnology Progress

Volumn 16, Issue 2, 2000, Pages 258-267

  Uludag, Hasan ^a   Kousinioris, Niki ^a   Gao, Tiejun ^a   Kantoci, Darko ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONATE CONJUGATION; BONE AFFINITY;

1 AMINO 1,1 DIPHOSPHONATE METHANE; 2 IMINOTHIOLANE; 4 (N MALEIMIDOMETHYL) 1 CYCLOHEXANECARBOXYLIC ACID SULFOSUCCINIMIDYL ESTER; ALBUMIN; BISPHOSPHONIC ACID DERIVATIVE; DERIVATIZATION; DESORPTION; LIGAND; OSSIFICATION; PROTEIN CONJUGATION; PROTEIN DERIVATIVE; PROTEIN; SORPTION;

AMINO ACIDS; BONE; CELLS; ORTHOPEDICS; PROTEINS;

BIOMEDICAL ENGINEERING;

ANIMALS; BONE AND BONES; CROSS-LINKING REAGENTS; DIPHOSPHONATES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DURAPATITE; FEMALE; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN, BOVINE;

EID: 0034096124     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1021/bp990154m     Document Type: Article

References (48)

1. Osteoporosis: Etiology, Diagnosis and Management, 2nd ed.; Riggs, B. L., Melton, L. J., Eds.; Lippincott-Raven Press: Philadelphia, 1995.
2. Kleerekoper, M.; Avioli, L. V. Evaluation and treatment of postmenopausal osteoporosis. In Primers on the Metabolic Bone Disease and Disorders of Mineral Metabolism, 2nd ed.; Favus, M. J., Ed; Raven Press: New York, 1993; pp 223-229.
3. Hanley, D.; Josse, R. G. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. Can. Med. Assoc. J. 1996, 155, 921-922.
4. Josse, R. et al. Clinical practice guidelines for the diagnosis and management of osteoporosis. Can. Med. Assoc. J. 1996, 155, 1113-1129.
5. Hinton, R. Y.; Lennox, D. W.; Ebert, F. R.; Jacobson, S. J.; Smith, G. S. Relative rates of fracture of the hip in the U. S. J. Bone Joint Surg. 1995, 77, 695-702.
6. Melton; L. J.; Atkinson, E. J.; O'Fallon, W. M.; Wahner, H. W.; Riggs, B. L. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J. Bone Miner. Res. 1993, 8, 1227-1233.
7. Ray, N. F.; Chan, J. K.; Thamer, M.; Melton, L. J. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J. Bone Miner. Res. 1997, 12, 24-35.
8. Hauchka, P. V.; Maurakos, A. E.; Iafradi, M. D.; Doleman, S. E.; Klagsbrun, M. Growth factors in bone matrix. J. Biol. Chem. 1986, 261, 12665-12674.
9. Taipale, J.; Keski-Oja, J. Growth factors in the extracellular matrix. FASEB J. 1997, 11, 51-59.
10. Trippel, S. B.; Coutts, R. D.; Einhorn, T. A.; Mundy, G. R.; Rosenfeld, R. G. Growth Factors as therapeutic agents. J. Bone Joint Surg. 1996, 78A, 1272-1286.
11. Reginster, J.-Y.; Taquet, A. N.; Gosset, C. Therapy for osteoporosis: miscellaneous and experimental agents. Endocrinol. Metab. Clin. North Am. 1998, 27, 453-463.
12. De Ligny, C. L.; Gelsema, W. J.; Tji, T. G.; Huigen, Y. M.; Vink, H. A. Bone-seeking radiopharmaceuticals. Nucl. Med. Biol. 1990, 17, 161-179.
13. Fogelman, I. Skeletal uptake of diphosphonate: a review. Eur. J. Nucl. Med. 1980, 5, 473-476.
14. Bernardi, G. Chromatography of nucleic acids on hydroxyapatite columns. Methods Enzymol. 1971, 31, 96-97.
15. Kantoci, D.; Denike, J. K.; Wechter, W. J. Synthesis of aminobisphosphonates. Synth. Comm. 1996, 26, 2037-2043.
16. Cayot, P.; Tainturier, G. The quantification of protein amino groups by the trinitrobenzenesulfonic acid method: a reexamination. Anal. Biochem. 1997, 249, 184-200.
17. Ellman, G. L. Tissue sulfphryl groups. Arch. Biochem. Biophys. 1959, 82, 70-77.
18. Riddles, P. W.; Blakeley, R. L.; Zerner, B. Reassessment of Ellman's reagent. Methods Enzymol. 1983, 91, 49-60.
19. Sober, H. A.; Harte, R. A. Handbook of Biochemistry, 2nd ed.; CRC Press: Cleveland, 1970; p C-36.
20. Bradford, M. M. A rapid and sensitive method for the quantification of microgram quantities of proteins utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
21. Ames, B. N. Assay of inorganic phosphate, total phosphate and phosphatases. Methods Enzymol. 1966, 8, 115-117.
22. Fraker, P. J.; Spack, J. C. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a, 6a-diphrenylglycoluril. Biochem. Biophys. Res. Commun. 1978, 80, 847-857.
23. Atassi, M. Z.; Kazim, A. L.; Sakata, S. High yield coupling of peptides to protein carriers. Biochim. Biophys. Acta 1981, 670, 300-302.
24. Russell, R. G. G.; Muhlbauer, R. C.; Bisaz, S.; Williams, D. A.; Fleisch, H. The influence of pyrophosphate, condensed phosphates, phosphonates, and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Cal. Tissue Res. 1970, 6, 183-196.
25. Van Gelder, J. M.; Breuer, E.; Ornoy, A.; Schlossman, A.; Patlas, N.; Golomb, G. Anti-calcification and antiresorbtion effects of bisacryphosphonates. Bone 1995, 16, 511-520.
26. van Beek, E.; Hoekstra, M.; van be Ruit, M.; Lowik, C.; Papapoulos, S. Structural requirements for bisphosphonate actions in vitro. J. Bone Miner. Res. 1994, 9, 1875-1882.
27. Gorbunoff, M. J. The interaction of proteins with hydroxyapatite. I. Role of protein charge and structure. Anal. Biochem. 1984, 736, 425-432.
28. Tournier, E. J. M.; Wallach, J.; Blond, P. Sulfosuccinimidyl 4-(N-maleimidomethyl)-1-cyclohexane carboxylate as a bifunctional immobilization agent. Optimization of the coupling conditions. Anal. Chim. Acta 1998, 361, 33-44.
29. Singh, R.; Kats, L.; Blattler, W. A.; Lambert, J. M. Formation of N-substituted 2-iminothiolanes when amino groups in proteins and peptides are modified by 2-iminothiolane. Anal. Biochem. 1996, 236, 114-125.
30. Lin, J. H.; Chen, I.-W.; Deluna, F. A.; Hichens, M. Role of calcium in plasma protein binding and renal handling of alendronate in hypo-and hypercalcemic rats. J. Pharmacol. Exp. Ther. 1993, 267, 670-675.
31. Daley-Yates, P. T.; Cal, J. C.; Cockshott, A.; Pongchaidecha, M.; Gilchrist, K. Plasma protein binding of APD: role of calcium and transferrin. Chem.-Biol. Interact. 1992, 81, 79-89.
32. Moreno, E. C.; Kresak, M.; Hay, D. I. Adsorption of molecules of biological interest onto hydroxyapatite. Calcif. Tissue Int. 1984, 36, 48-59.
33. Lou, Q.; Andrade, J. D. Cooperative adsorption of proteins onto hydroxyapatite. J. Colloid Interface Sci. 1998, 200, 104-113.
34. Norde, W.; Haynes, C. A. Thermodynamics of protein adsorption. In Interfacial Phenomena and Bioproducts; Brash, J. L., Wojciechowski, P. W., Eds.; Marcel Dekker: New York, 1996; pp 135-137.
35. Uludag, H.; Golden, J.; Palmer, R.; Wozney, J. M. Biotinated recombinant human Bone Morphogenetic Protein-2: In vitro and in vivo activity. Biotech. Bioeng. 1999, 65, 668-672.
36. Pieri, I.; Barritault, D. Biotinylated basic Fibroblast Growth Factor is biologically active. Anal. Biochem. 1991, 195, 214-219.
37. Pongchaidecha, M.; Dales-Yates, P. T. Clearence and tissue uptake following 4-hour and 24-hour infusion of pamidronate in rats. Drug Metab. Dispos. 1993, 21, 100-104.
38. Schenk, R.; Eggli, P.; Fleisch, H.; Rosini, S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphophonates on bone resorption in the rat. Calcif. Tissue Int. 1986, 38, 342-349.
39. Nakamura, T.; Handa, K.; Tamura, M.; Shibaunuchi, T.; Nigi, H.; Tagawa, M.; Fukumoto, S.; Matsumoto, T. Stimulation of endosteal bone formation by systemic injections of recombinant basic Fibroblast growth factor in rats. Endocrinology 1995, 136, 1276-1284.
40. Bagi, C. M.; DeLeon, E.; Brommage, G.; Rosen, D.; Sommer, A. Treatment of ovariectomized rats with the complex of rhIGF-1/IGFBP-3 increases cortical and cancelous bone mass and improves structure in the femoral neck. Calcif. Tissue Int. 1995, 57, 40-46.
41. Bentz, H.; Rosen, D. Targeted delivery of bone growth factors. EP 0512 844A1, 1992.
42. Wingen, F.; Sterz, H.; Blum, H.; Moller, H.; Pittermann, W.; Pool, B. L.; Sinn, H. J.; Spring, H.; Schmahl, D. Synthesis, antitumor activity, distribution and toxicity of 4-[4-[bis(2-chloroethyl)amino]phenyl]-1-hydroxybutane-1-1-bisphosphonic acid (BAD), a new lost derivative with increased accumulation in rat osteosarcoma. J. Can. Res. Clin. Oncol. 1986, 111, 209-219.
43. Klenner, T.; Wingen, F.; Keppler, B. P.; Krempien, B.; Schmahl, D. Anti-cancer-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies. J. Can. Res. Clin. Oncol. 1990, 116, 341-350.
44. Hosain, F.; Spencer, R. P.; Couthon, H. M.; Sturtz, G. L. Targeted delivery of antineoplastic agent to bone: biodistribution studies with technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate. J. Nucl. Med. 1996, 37, 105-107.
45. Sturtz, G.; Couthon, H.; Fabulet, O.; Mian, M.; Rosini, S. Synthesis of gem-bisphosphonic methotrexate conjugates and their biological response towards Walker's osteosarcoma. Eur. J. Med. Chem. 1993, 28, 899-903.
46. Bauss, F.; Esswein, A.; Reiff, K.; Sponer, G.; Muller-Beckmann, M. Effect of 17β-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17β-estradiol serum kinetics on bone mass in rats. Calcif. Tissue Int. 1996, 59, 168-173.
47. Fujisaki, J.; Tokunaga, Y.; Takahashi, T.; Kimura, S.; Shimojo, F.; Hata, T. Osteoporotic drug delivery system (ODDS) based on bisphosphonic prodrug: V Biological disposition and targeting characteristics of osteotropic estradiol. Biol. Pharm. Bull. 1997, 20, 1183-1187.
48. Fujisaki, J.; Tokunaga, Y.; Takahashi, T.; Shimojo, F.; Kimura, S.; Hata, T. Osteoporotic drug delivery system (ODDS) based on bisphosphonic prodrug: IV Effects of osteotropic estradiol on bone mineral density and uterine weight in overiectomized rats. J. Drug Target. 1997, 5, 129-138.